| 注册
首页|期刊导航|临床肝胆病杂志|《2025年美国肝病学会实践指导:肝细胞癌的预防、诊断和治疗(关键更新)》解读

《2025年美国肝病学会实践指导:肝细胞癌的预防、诊断和治疗(关键更新)》解读

赵宇泽 陈宇枭 王科淳 王明达 杨田

临床肝胆病杂志2025,Vol.42Issue(5):851-854,4.
临床肝胆病杂志2025,Vol.42Issue(5):851-854,4.DOI:10.12449/JCH250509

《2025年美国肝病学会实践指导:肝细胞癌的预防、诊断和治疗(关键更新)》解读

Interpretation of critical update:AASLD practice guidance on prevention,diagnosis,and treatment of hepatocellular carcinoma

赵宇泽 1陈宇枭 1王科淳 2王明达 2杨田2

作者信息

  • 1. 海军军医大学东方肝胆外科医院肝外二科,上海 200438||海军军医大学基础医学院,上海 200438
  • 2. 海军军医大学东方肝胆外科医院肝外二科,上海 200438
  • 折叠

摘要

Abstract

In February 2025,the American Association for the Study of Liver Diseases(AASLD)published online"Critical Update:AASLD Practice Guidance on Prevention,Diagnosis,and Treatment of Hepatocellular Carcinoma".This update mainly focuses on the latest analysis results of the IMbrave050 study and performs corresponding updates and adjustments to recommendations based on the issues in clinical practice.As for the postoperative adjuvant therapeutic strategies for hepatocellular carcinoma(HCC)based on immune checkpoint inhibitors,the AASLD has re-evaluated and updated the practice guidance.The update revises related texts and recommendations for adjuvant therapy and the management algorithms for HCC recurrence during or after adjuvant therapy.Furthermore,the AASLD emphasizes that even for HCC patients at a high risk of recurrence after resection or local ablation,close monitoring for recurrence remains the current standard treatment regimen.Our team makes an excerpt of the update,systematically introduces the background and specific contents of the update,and discuss the adjuvant therapy for HCC,in order to provide a reference for readers.

关键词

癌,肝细胞/预防/诊断/治疗学/美国/共识

Key words

Carcinoma,Hepatocellular/Prevention/Diagnosis/Therapeutics/United States/Consensus

引用本文复制引用

赵宇泽,陈宇枭,王科淳,王明达,杨田..《2025年美国肝病学会实践指导:肝细胞癌的预防、诊断和治疗(关键更新)》解读[J].临床肝胆病杂志,2025,42(5):851-854,4.

基金项目

国家自然科学基金(82425049,82273074,81972726) (82425049,82273074,81972726)

上海市优秀学术带头人计划项目(23XD1424900) (23XD1424900)

上海市卫生健康学科带头人项目(2022XD001) (2022XD001)

上海市自然科学基金(22ZR1477900) National Natural Science Foundation of China(82425049,82273074,81972726) (22ZR1477900)

Shanghai Outstanding Academic Leader Program(23XD1424900) (23XD1424900)

Shanghai Health Academic Leader Program(2022XD001) (2022XD001)

Natural Science Foundation of Shanghai(22ZR1477900) (22ZR1477900)

临床肝胆病杂志

OA北大核心

1001-5256

访问量3
|
下载量0
段落导航相关论文